Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Bladder Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Bladder Cancer
    New Treatment Strategy Improves Depression in Patients With Cancer - (DGNews)
    TopAbstracts in Bladder Cancer 07/02/2008 - (DGNews)
    Researchers Evaluate the Role of Chemotherapy at the End of Life - (DGNews)
    TopAbstracts in Bladder Cancer 06/04/2008 - (DGNews)
    TopAbstracts in Bladder Cancer 05/07/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Bladder Cancer

    Webcasts/CME archive

     Recent cases - Bladder Cancer
      Adenocarcinoma of the Bladder Following Nephrogenic Adenoma: A Case Report
      The First Case of Vesico-Vaginal Fistula in a Patient with Primary Lymphoma of the Bladder: A Case Report
      Vacuum-Assisted Closure Therapy in Ureteroileal Anastomotic Leakage after Surgical Therapy of Bladder Cancer
      Granular Cell Tumors of the Urinary Bladder
      Granulomatous Hepatitis after Intravesical BCG Treatment for Bladder Cancer

      Cases archive
        




      my personal edition > bladder cancer > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Bacillus Calmette-Guerin Treatment Reduces Recurrence of Bladder Cancer Compared to Mitomycin C

      A DGReview of :"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials"
      British Journal of Urology (BJU International)

      03/25/2004
      By Emma Hitt, PhD


      Intravesical bacillus Calmette-Guerin (BCG) treatment appears to reduce the recurrence rate of bladder cancer compared to mitomycin C, but only in those patients at high risk of tumour recurrence, according to new research.

      Intravesical BCG is significantly more effective than is transurethral resection alone in the prophylaxis of Ta and T1 bladder cancer, but the role of BCG compared with other intravesical agents is unclear.

      Mike Shelley, MD, with the University Hospital of Wales, in Cardiff, United Kingdom, and colleagues conducted a systematic review and meta-analysis of the relative effectiveness of intravesical mitomycin C and BCG for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer.

      The researchers searched major medical databases and relevant journals for randomised controlled trials, in any language and found 7 eligible articles, representing 1901 evaluable patients. Of the patients, 820 were randomised to mitomycin C and 1081 to BCG. Six trials had sufficient data for meta-analysis.

      No significant difference was observed between mitomycin C and BCG for tumour recurrence in the six trials. However, significant heterogeneity was present between trials (P = 0.001).

      A subgroup analysis of three trials including only high-risk Ta and T1 patients indicated no heterogeneity (P = 0.25). With mitomycin C used as the control in the meta-analysis, a negative ratio was in favour of BCG and was highly significant (P < 0.001).

      The seventh trial used BCG in low doses for two arms of the trial (27 mg and 13.5 mg) compared with a standard dose of mitomycin C (30 mg), and recurrence rate was significantly lower for BCG (27 mg) than for mitomycin C (P = 0.001).

      Two trials included sufficient data to analyse disease progression and survival, and disease progression (P = 0.16) and survival (P= 0.50) were similar.

      Adverse effects included dysuria, cystitis, frequency and haematuria and were associated with both mitomycin C (30%) and BCG (44%). Systemic toxicity occurred with both agents (12% and 19%, respectively) although skin rash was more common with mitomycin C.

      "It is unclear why intravesical BCG should be more effective than mitomycin C in high-risk patients. It may be that in high-risk tumors, the relatively reduced action of mitomycin C relates to poor drug absorption, as mitomycin C penetration depth is an important determinant of treatment effectiveness," Dr. Shelley and colleagues note.



      Br J Urol 2004;93:485-490. "Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send